Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB

Key facts

Sponsor

Prof Gerhard Walzl

Principal Investigator

Gerhard Walzl, PhD, MD

Head of Department of Biomedical Sciences

Intervention

Trans-Dot point-of-care test(diagnostic_test)

Enrollment

969 target

Eligibility

18-70 years · All sexes

Timeline

2016 – 2020

Study locations (10)

• Armauer Hansen Research Institute, Addis Ababa, Ethiopia
• European Research and Project Office GmbH, Saarbrücken, Saarland, Germany
• LINQ Management GmbH, Berlin, Germany
• University of Namibia, Windhoek, Namibia
• The European & Developing Countries Clinical Trials Partnership Association (EDCTP), The Hague, South Holland, Netherlands
• Leiden University Medical Center (Academisch Ziekenhuis Leiden, LUMC), Leiden, Netherlands
• Stellenbosch University, Cape Town, Western Cape, South Africa
• Medical Research Council The Gambia, Banjul, The Gambia
• Makerere University, Kampala, Uganda
• London School of Hygiene and Tropical Medicine, London, United Kingdom

Collaborators

Armauer Hansen Research Institute, Ethiopia · Medical Research Council Unit, The Gambia · Leiden University Medical Center · Makerere University · London School of Hygiene and Tropical Medicine · European and Developing Countries Clinical Trials Partnership (EDCTP) · LINQ Management GMBH

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary pulmonary tuberculosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07484490
  Effects of the Active Cycle of Breathing Technique With and Without Balloon Blowing Therapy in Tuberculosis
  Riphah International University
• RECRUITINGPHASE3NCT07209761
  A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
  Otsuka Pharmaceutical Development & Commercialization, Inc.
• RECRUITINGPHASE2NCT07170800
  A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets
  WestVac Biopharma Co., Ltd.
• RECRUITINGPHASE2NCT06192160
  Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGPHASE2NCT06748937
  A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide
  TASK Applied Science
• ACTIVE NOT RECRUITINGNANCT07186478
  I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis
  Hasanuddin University
• ACTIVE NOT RECRUITINGPHASE3NCT06649721
  Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort
  Huashan Hospital
• RECRUITINGPHASE4NCT06476210
  The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)
  Beijing Chest Hospital

See all trials for Primary pulmonary tuberculosis →